Accès direct au contenu


Version anglaise


Accueil > la Recherche au Centre Borelli > Bioinformatique

BiMoDyM - References

BiMoDyM: Bibliographic References


1.      Allain A., Chauvot de Beauchêne I., Langenfeld F., Guarracino Y., Laine E., and Tchertanov L. (2014). Allosteric Pathway Identification through Network Analysis from Molecular Dynamics Simulations to Interactive 2D and 3D Graphs. Faraday Disc., DOI:10.1039/C4FD00024B. 169, 1-18.

2.      Bibi S., Arslanhan M. D., Langenfeld F., Jeanningros S., Cerny-Reiterer S., Hadzijusufovic E., Tchertanov L., Moriggl R., Valent P., Arock M. (2014). Cooperating STAT5 and AKT signaling pathways in Chronic Myeloid Leukemia and Mastocytosis: Possible new Targets of Therapy. Haematologica. 99(3): 417-429. Da Silva Figueiredo Celestino Gomes P., Panel N., Laine E., Pascutti P. G., Solary E. and Tchertanov L. (2014). Differential effects of CSF-1R D802V and KIT D816V homologous mutations on receptor tertiary structure and allosteric communication. PLOS ONE. May 14;9(5):e97519. doi: 10.1371/journal.pone. 0097519.

3.      Vita M, Tisserand J C, Chauvot de Beauchêne I, Panel N, Tchertanov L, Mescam-Mancini L, Agopian J, Fouet B, Fournier B, Dubreuil P, Bertucci F, and De Sepulveda P. (2014). Characterization of S628N, a novel KIT mutation found in a metastatic melanoma. JAMA Dermatology, doi:10.1001/jamadermatol.2014.143.

4.      Chauvot de Beauchêne I., Alain A., Panel N., Laine E., Trouvé A., Dubreuil P. and Tchertanov L. (2014). Oncogenic mutations of KIT receptor differentially modulate tyrosine kinase activity and drug susceptibility. PLOS Comput. Biol.;10(7):e1003749. doi: 10.1371/journal.pcbi.1003749.

5.      Arlet J.B., Ribeil J. A., Hazoume A., Demarest S., Chauvot de Beauchêne I., Negre O., Dussiot M., Moura I. C., Sevin M., Maciel T. T., Auclair C., Belaid-Choucair Z., Leboulch P., Beuzard Y., Baudin-Creuza V., Tchertanov L., Garrido C., Hermine O., Courtois G. (2014). Hsp70 cytosolic sequestration by excess of free a-globin promotes ineffective erythropoiesis in -thalassemia. Nature. Aug 24. doi: 10.1038/nature13614.

6.      Gardie B., Couvé, S., Ladroue, C., Laine, E., Mathouk, K., Guégan, J., Gad, S.,  Lejeune, H. Lecomte, B. ,  Pagès, J.-C.,  Collin, C., Lasne F., Bressac de Paillerets, B., Feunteun, J. Dessen, P.,  Lazar, V., Tchertanov, L., Mole, D., Kaelin, W., Ratcliffe, P., Richard, S. (2014). A comprehensive study of germline mutations in the VHL gene reveals the importance of precisely tuned dysregulation of the hypoxia pathway in oncogenesis. CANCER RESEARCH.Nov 15; 74(22):6554-64. doi: 10.1158/0008-5472.CAN-14-1161.

7.      De Vuyst F., Guillas S., Kendira A., Labourdette C., Tchertanov L. (2014). L'ENS Cachan voit grand avec le mur d'image SHIVA. HPC Today. 26 sept. 2014.

8.      McIntosh-Smith, Tchertanov, Nerukh, Stone, Baaden, Hayward, Glowacki, Olson, Zoppè, Petrov, Hall, Reiher, Brancale, Haag, O'Donoghue, Brooks, Raffin, Iakovou, Chavent, Montes, Baker, Thomas, Woods, Hirst. (2014). Computing power revolution and new algorithms: GP-GPUs, clouds and more: general discussion. Faraday Discuss.; 169:379-401. doi: 10.1039/c4fd90021a.

9.      Chapuzet A., Goulois J., Chatron N., Tchertanov L., Lambert V. Benoit E., Lattard V. (2015). The first detection of a target resistance to antivitamin K rodendicides in the black rat Rattus - Identification and characterization of a new mutation in the VKORC1. Pest Management Science. Apr 7. doi: 10.1002/ps.4020.

10.   Langenfeld F., Guarracino Y., Arock M., Trouvé and Tchertanov L. (2015). How intrinsic molecular dynamics controls intramolecular communication in Signal Transducers and Activators of Transcription Factor STAT5. PLOS ONE. Dec 30;10(12):e0145142. doi: 10.1371/journal.pone.0145142. E-Collection 2015.

11.   Langenfeld F., Guarracino Y., Arock M., Trouvé and Tchertanov L. (2016).  How Intrinsic Molecular Dynamics Control Intramolecular Communication in the Signal Transducers and Activators of Transcription Factor STAT5. Invited Research highlight for World Biomedical Frontiers.

12.   Da Silva Figueiredo Celestino Gomes P., Chauvot de Beauchêne I., Panel N., Pascutti P., Solary E., and Tchertanov L. Insight on Mutation-Induced Resistance from Molecular Dynamics Simulations of Wild-type and mutated CSF-1R and KIT. (2016) PLoS ONE.11(7):e0160165. doi: 10.1371/journal.pone.0160165. eCollection 2016.

13.   Chauvot de Beauchêne I. and Tchertanov L. (2016). How Missense Mutations in Receptors Tyrosine Kinases impact Constitutive Activity and alternate Drug Sensitivity: Insights from Molecular Dynamics Simulations. Invited Research highlight for Receptors & Clinical Investigation. Vol.3, e1372. doi: 10.14800/rci.1372.

14.   Jouenne F., Chauvot de Beauchêne, Caron O., Ingster O., Avril M-F, Caumette V.,  Lecesne A., Benusiglio P., Terrier P., Pissaloux D., De la Fouchardière A, Soto Kiando R., Coupier I., Velghe A., Bollaert E., Bougeard G., Mann G., Harland M., Newton-Bishop J., Gruis M., Van Doorn R., Guimbaud R., Delnatte C., Bertolotto C., Demenais F., Eggermont A., Feunteun J., Bouatia-Naji N., Tchertanov L., Demoulin J.-B., Frebourg T., Bressac de Paillerets B. (2017) CDKN2A is also a sarcoma predisposing gene, in addition to melanoma. J Med Genet. 2017 Jun 7. pii: jmedgenet-2016-104402. doi: 10.1136/jmedgenet-2016-104402.

15.   Chatron N., Chalmond B., Trouvé A., Benoît E., Caruel H., Lattard V., Tchertanov L. (2017). Identification of the Functional States of Human Vitamin K Epoxide Reductase from Molecular Dynamics Simulations. RSC Advances, 7, 52071 - 52090.

16.   Palmai Z., Arfi K., Cohen-Kaminsky, Tchertanov L. (2017). The effect of ligands binding onto the functional dynamics of human N-methyl-D-aspartate receptor (hNMDAR). PLOS ONE. Submitted.

  • The First Prix of The Royal Chemical Society at the Molecular Simulation and Visualisations, Faraday Discussion' -2014 at Nottingham (UK) for the method and results presented in [1].

  • The paper reported the recognition of the Chaperone Hsp70 by the Globins was published in Nature 2014, Aug 24. doi: 10.1038/nature13614 [5].

  • In 2015, our study of allostery [1], [4], [10-12] the method development and its application to proteins was recognized by International Innovation ( as "an important contribution to the innovative strategy of clinical and therapeutic interest".

  • Our entire results on allostery were considered as "very interesting and impressive" and was published in Receptors & Clinical Investigation [13].

  • The paper [10] was choice "to be featured in the World Biomedical Frontiers, because of its innovation and potential for significant impact" [11].

  • The keynote/plenary lecture (L. Tchertanov) at the 3rd International Conference and Expo on Drug Discovery & Designing. October 02-04, 2017 Vienna, Austria.